Denali Therapeutics Inc.
DNLI
$14.80
$0.432.99%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -7.37% | -13.76% | 9.47% | -5.43% | -87.31% |
| Gross Profit | 7.37% | 13.76% | -11.04% | -105.15% | 82.55% |
| SG&A Expenses | 16.31% | 21.36% | -1.48% | -3.55% | -7.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.08% | -7.56% | 7.06% | -5.70% | -15.20% |
| Operating Income | -10.08% | 7.56% | -8.25% | -168.39% | -9.47% |
| Income Before Tax | -30.62% | 3.98% | -7.89% | -154.00% | 7.27% |
| Income Tax Expenses | -- | 126.67% | -- | -- | -- |
| Earnings from Continuing Operations | -30.62% | 3.95% | -7.89% | -154.00% | 7.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.62% | 3.95% | -7.89% | -154.00% | 7.27% |
| EBIT | -10.08% | 7.56% | -8.25% | -168.39% | -9.47% |
| EBITDA | -10.12% | 6.31% | -8.37% | -166.36% | -17.44% |
| EPS Basic | -13.97% | 21.93% | 12.36% | -143.83% | 15.26% |
| Normalized Basic EPS | 5.86% | 29.63% | 12.35% | -143.84% | 1.45% |
| EPS Diluted | -13.97% | 21.93% | 12.36% | -145.38% | 15.26% |
| Normalized Diluted EPS | 5.86% | 29.63% | 12.35% | -145.08% | 1.45% |
| Average Basic Shares Outstanding | 14.60% | 23.03% | 23.11% | 23.19% | 9.43% |
| Average Diluted Shares Outstanding | 14.60% | 23.03% | 23.11% | 19.80% | 9.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |